Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 50 | 2016 | 3639 | 3.870 |
Why?
|
| Kidney | 19 | 2016 | 1135 | 3.190 |
Why?
|
| Oxygen | 18 | 2016 | 781 | 2.870 |
Why?
|
| Osteoarthritis, Knee | 9 | 2011 | 71 | 1.400 |
Why?
|
| Contrast Media | 19 | 2016 | 1096 | 1.280 |
Why?
|
| Cartilage, Articular | 10 | 2011 | 78 | 1.100 |
Why?
|
| Kidney Medulla | 7 | 2007 | 79 | 1.050 |
Why?
|
| Gadolinium DTPA | 9 | 2011 | 255 | 0.940 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2016 | 700 | 0.930 |
Why?
|
| Renal Circulation | 3 | 2014 | 37 | 0.920 |
Why?
|
| Kidney Diseases | 5 | 2015 | 323 | 0.880 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2016 | 276 | 0.850 |
Why?
|
| Furosemide | 7 | 2016 | 33 | 0.820 |
Why?
|
| Nitric Oxide Synthase | 3 | 2011 | 123 | 0.810 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 116 | 0.720 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2010 | 630 | 0.650 |
Why?
|
| NG-Nitroarginine Methyl Ester | 5 | 2016 | 45 | 0.640 |
Why?
|
| Oxygen Consumption | 7 | 2016 | 253 | 0.620 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2016 | 1267 | 0.600 |
Why?
|
| Osteoarthritis | 4 | 2008 | 85 | 0.600 |
Why?
|
| Diuretics | 5 | 2014 | 77 | 0.580 |
Why?
|
| Diabetic Nephropathies | 2 | 2010 | 90 | 0.570 |
Why?
|
| Rats | 12 | 2016 | 4154 | 0.560 |
Why?
|
| Triiodobenzoic Acids | 4 | 2015 | 8 | 0.550 |
Why?
|
| Diuresis | 3 | 2011 | 26 | 0.480 |
Why?
|
| Sensitivity and Specificity | 10 | 2016 | 2039 | 0.450 |
Why?
|
| Manganese | 2 | 2006 | 57 | 0.440 |
Why?
|
| Renal Artery | 1 | 2014 | 46 | 0.420 |
Why?
|
| Knee | 2 | 2011 | 20 | 0.410 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 68 | 0.410 |
Why?
|
| Animals | 27 | 2017 | 28889 | 0.400 |
Why?
|
| Water | 3 | 2011 | 307 | 0.400 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 151 | 0.400 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 51 | 0.400 |
Why?
|
| Oximetry | 2 | 2016 | 90 | 0.400 |
Why?
|
| Knee Joint | 5 | 2011 | 166 | 0.390 |
Why?
|
| Ureteral Obstruction | 1 | 2013 | 70 | 0.390 |
Why?
|
| Male | 36 | 2016 | 45686 | 0.380 |
Why?
|
| Image Enhancement | 3 | 2013 | 565 | 0.380 |
Why?
|
| Hypoxia | 3 | 2017 | 681 | 0.380 |
Why?
|
| Nitric Oxide | 2 | 2011 | 281 | 0.370 |
Why?
|
| Disease Models, Animal | 7 | 2015 | 2534 | 0.370 |
Why?
|
| Dextrans | 1 | 2011 | 78 | 0.340 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 432 | 0.340 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 2882 | 0.330 |
Why?
|
| Glucose | 2 | 2011 | 701 | 0.330 |
Why?
|
| Kidney Tubules | 1 | 2011 | 91 | 0.330 |
Why?
|
| Nitric Oxide Donors | 1 | 2010 | 13 | 0.330 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2010 | 40 | 0.330 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 37 | 0.330 |
Why?
|
| Hypertension | 2 | 2005 | 774 | 0.280 |
Why?
|
| Artifacts | 3 | 2004 | 252 | 0.260 |
Why?
|
| Spin Labels | 3 | 2014 | 107 | 0.260 |
Why?
|
| Whole Body Imaging | 1 | 2007 | 40 | 0.250 |
Why?
|
| Blood Flow Velocity | 4 | 2014 | 201 | 0.250 |
Why?
|
| Free Radical Scavengers | 2 | 2014 | 60 | 0.250 |
Why?
|
| Humans | 39 | 2016 | 95802 | 0.230 |
Why?
|
| Liver | 1 | 2010 | 1231 | 0.230 |
Why?
|
| Female | 27 | 2017 | 49872 | 0.230 |
Why?
|
| Cyclic N-Oxides | 1 | 2005 | 33 | 0.230 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2004 | 172 | 0.220 |
Why?
|
| Drinking | 1 | 2004 | 35 | 0.210 |
Why?
|
| Bone Malalignment | 3 | 2011 | 6 | 0.210 |
Why?
|
| Magnetite Nanoparticles | 2 | 2016 | 27 | 0.210 |
Why?
|
| Adult | 16 | 2015 | 28578 | 0.190 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 472 | 0.190 |
Why?
|
| Phantoms, Imaging | 6 | 2010 | 490 | 0.190 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 429 | 0.180 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 167 | 0.180 |
Why?
|
| Kidney Cortex | 3 | 2007 | 32 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 258 | 0.170 |
Why?
|
| Middle Aged | 17 | 2014 | 28208 | 0.170 |
Why?
|
| Lipocalins | 3 | 2015 | 34 | 0.170 |
Why?
|
| Acute-Phase Proteins | 3 | 2015 | 36 | 0.170 |
Why?
|
| Ions | 2 | 2011 | 79 | 0.170 |
Why?
|
| Heart | 2 | 2003 | 590 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 1 | 2002 | 467 | 0.160 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 341 | 0.160 |
Why?
|
| Iron | 2 | 2014 | 179 | 0.150 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1957 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2002 | 662 | 0.140 |
Why?
|
| Reference Values | 3 | 2004 | 674 | 0.140 |
Why?
|
| Feasibility Studies | 6 | 2014 | 816 | 0.130 |
Why?
|
| Swine | 3 | 2010 | 598 | 0.130 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2017 | 18 | 0.130 |
Why?
|
| Uterine Contraction | 1 | 2017 | 8 | 0.130 |
Why?
|
| Visceral Pain | 1 | 2017 | 6 | 0.130 |
Why?
|
| Hyperalgesia | 1 | 2017 | 22 | 0.130 |
Why?
|
| Platelet Activating Factor | 1 | 2017 | 53 | 0.130 |
Why?
|
| Time Factors | 5 | 2011 | 5561 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 684 | 0.130 |
Why?
|
| Aged | 15 | 2014 | 20848 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1965 | 0.130 |
Why?
|
| Theranostic Nanomedicine | 1 | 2016 | 2 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 165 | 0.120 |
Why?
|
| Uterus | 1 | 2017 | 228 | 0.120 |
Why?
|
| Mice | 5 | 2017 | 12537 | 0.110 |
Why?
|
| Metals | 1 | 2016 | 101 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 2015 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 771 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 3491 | 0.110 |
Why?
|
| Rats, Inbred SHR | 2 | 2005 | 33 | 0.110 |
Why?
|
| Rats, Inbred WKY | 2 | 2005 | 31 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 74 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2014 | 73 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 201 | 0.100 |
Why?
|
| Vasoconstriction | 1 | 2014 | 93 | 0.100 |
Why?
|
| Vasodilation | 1 | 2014 | 96 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 2 | 2011 | 19 | 0.100 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 115 | 0.100 |
Why?
|
| Tibial Meniscus Injuries | 2 | 2010 | 19 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 246 | 0.100 |
Why?
|
| Nephrology | 1 | 2013 | 46 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1176 | 0.090 |
Why?
|
| Viscosity | 1 | 2012 | 51 | 0.090 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 180 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 623 | 0.090 |
Why?
|
| Menisci, Tibial | 2 | 2010 | 26 | 0.090 |
Why?
|
| Models, Theoretical | 2 | 2006 | 503 | 0.090 |
Why?
|
| Hippocampus | 1 | 2014 | 459 | 0.090 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 259 | 0.080 |
Why?
|
| Nitroimidazoles | 1 | 2010 | 9 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 21 | 0.080 |
Why?
|
| Splanchnic Circulation | 1 | 2010 | 14 | 0.080 |
Why?
|
| Swine, Miniature | 1 | 2010 | 56 | 0.080 |
Why?
|
| Lipocalin-2 | 3 | 2015 | 39 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2013 | 936 | 0.080 |
Why?
|
| Heart Diseases | 2 | 2004 | 314 | 0.080 |
Why?
|
| Prostaglandins | 1 | 2010 | 44 | 0.080 |
Why?
|
| Naproxen | 1 | 2010 | 15 | 0.080 |
Why?
|
| Knee Injuries | 1 | 2010 | 53 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2010 | 163 | 0.080 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 37 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1878 | 0.080 |
Why?
|
| Patellofemoral Joint | 1 | 2009 | 19 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 606 | 0.080 |
Why?
|
| Tibia | 1 | 2009 | 80 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2010 | 181 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 7215 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2004 | 1319 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 249 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 848 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 747 | 0.070 |
Why?
|
| Adenosine | 1 | 2011 | 278 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 655 | 0.070 |
Why?
|
| Biomarkers | 4 | 2014 | 1931 | 0.070 |
Why?
|
| Renal Artery Obstruction | 1 | 2007 | 19 | 0.070 |
Why?
|
| Arthrography | 1 | 2007 | 8 | 0.070 |
Why?
|
| Leg Bones | 1 | 2007 | 7 | 0.070 |
Why?
|
| Streptozocin | 1 | 2007 | 56 | 0.060 |
Why?
|
| Magnetics | 1 | 2007 | 43 | 0.060 |
Why?
|
| Joint Instability | 1 | 2008 | 99 | 0.060 |
Why?
|
| Fiber Optic Technology | 1 | 2007 | 36 | 0.060 |
Why?
|
| Pain | 1 | 2009 | 426 | 0.060 |
Why?
|
| Angioplasty, Balloon | 1 | 2007 | 98 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2007 | 309 | 0.060 |
Why?
|
| Age Factors | 1 | 2010 | 1957 | 0.060 |
Why?
|
| Echo-Planar Imaging | 1 | 2006 | 52 | 0.060 |
Why?
|
| Hepatic Artery | 1 | 2005 | 84 | 0.060 |
Why?
|
| Dogs | 1 | 2006 | 718 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 44 | 0.050 |
Why?
|
| Ioxaglic Acid | 2 | 2014 | 7 | 0.050 |
Why?
|
| Iohexol | 2 | 2014 | 23 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 1124 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1809 | 0.050 |
Why?
|
| Myocardium | 2 | 2004 | 592 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 111 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 33 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 263 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 279 | 0.050 |
Why?
|
| Respiration | 1 | 2004 | 281 | 0.050 |
Why?
|
| Motion | 1 | 2002 | 99 | 0.050 |
Why?
|
| Diaphragm | 1 | 2003 | 75 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 286 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 253 | 0.040 |
Why?
|
| Body Height | 1 | 2002 | 108 | 0.040 |
Why?
|
| Creatinine | 1 | 2002 | 299 | 0.040 |
Why?
|
| Observer Variation | 1 | 2002 | 626 | 0.040 |
Why?
|
| Weight-Bearing | 2 | 2011 | 73 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2773 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 460 | 0.040 |
Why?
|
| Perfusion | 2 | 2017 | 266 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2004 | 775 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2002 | 531 | 0.040 |
Why?
|
| Lung | 2 | 2003 | 1380 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2011 | 10273 | 0.040 |
Why?
|
| Adolescent | 1 | 2011 | 9873 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 281 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2002 | 926 | 0.030 |
Why?
|
| Biomechanical Phenomena | 2 | 2011 | 506 | 0.030 |
Why?
|
| Dinoprost | 1 | 2017 | 27 | 0.030 |
Why?
|
| Oxytocin | 1 | 2017 | 75 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2007 | 100 | 0.030 |
Why?
|
| Disease Progression | 2 | 2010 | 1559 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 522 | 0.030 |
Why?
|
| Iothalamic Acid | 1 | 2014 | 9 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 283 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 376 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 3106 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2161 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3904 | 0.020 |
Why?
|
| Bone Cysts | 1 | 2010 | 8 | 0.020 |
Why?
|
| Cartilage Diseases | 1 | 2010 | 18 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2010 | 53 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 599 | 0.020 |
Why?
|
| Posture | 1 | 2008 | 130 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 138 | 0.020 |
Why?
|
| Hip Joint | 1 | 2007 | 56 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2007 | 60 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 311 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 713 | 0.020 |
Why?
|
| Liver Circulation | 1 | 2005 | 30 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 2005 | 49 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 1714 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1981 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 797 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 639 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 823 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 426 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 908 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5961 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 790 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 4664 | 0.010 |
Why?
|